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ABSTRACT
Introduction: Prior studies suggested that a
routine invasive approach in the management
of non-ST-elevation acute coronary syndrome
(NSTE-ACS) is beneficial in men, but the data
are less conclusive in women. One study
conducted exclusively in women found that
routine invasive therapy was associated with a
markedly increased risk of major bleeding. This
pilot randomized controlled trial compared the
safety of a routine invasive versus a selective
invasive strategy among women.
Methods: Women with NSTE-ACS and an
additional high-risk characteristic were
randomized to a routine invasive versus a
selective invasive strategy. The primary outcome
was the risk of major bleeding. The secondary
outcomewas thefirst occurrenceof all-causedeath,
myocardial infarction, stroke, re-hospitalization
for ACS, or major bleeding within 6months.
Results: Twenty-three women were assigned to
routine invasive therapy and 17 to selective
invasive therapy. Twenty-seven women (68%)
had elevated troponin T (mean 0.33 ng/mL)
and/or creatinine kinase-MB (mean 23 ng/mL).
The risk of major bleeding was similar with both
approaches (P = 0.99). At 6 months, the
secondary outcome occurred in 9% of the
routine invasive group versus 18% of the
selective invasive group (risk ratio = 0.49,
95% confidence interval 0.09–2.63, P = 0.63).
Conclusion: This pilot study demonstrated that
a routine invasive approach is safe in women.
There was suggestion of benefit from routine
invasive therapy compared with selective
invasive therapy. These data could be used to
design an appropriately powered trial to
determine the optimal management strategy
among women with NSTE-ACS.
Keywords: Major bleeding; Myocardial
infarction; Non-ST-elevation acute coronary
syndrome; Sex differences; Women
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INTRODUCTION
The efficacy and safety of routine invasive
versus selective invasive therapy may not
apply similarly to women and men with
non-ST-elevation acute coronary syndrome
(NSTE-ACS). Meta-analyses have documented a
reduction in death or myocardial infarction
among NSTE-ACS men that undergo routine
invasive therapy [1, 2]. However, benefit has
been more difficult to detect among NSTE-ACS
women who undergo routine invasive therapy.
In addition to bleeding differences [3], women
appear to be more likely to present with normal
or less severe coronary artery disease [4, 5]. The
only randomized trial conducted exclusively in
women comparing both approaches
documented a non-significant increase in
death or myocardial infarction among
invasively treated women. In fact, invasive
therapy was associated with excess mortality at
1 year [6]. In that study, the risk of major
bleeding was approximately 9% at 30 days in
the routine invasive arm. The patients were
treated with either low molecular weight
heparin or fondaparinux, which could have
contributed to the increased bleeding [7, 8]. The
aim of this study was to compare the safety of
routine invasive versus conservative strategies
in women who are treated with contemporary
medical therapy for NSTE-ACS and to determine
the adequate sample size for a randomized
clinical trial should this approach appear to be
safe.
METHODS
Women at least 18 years of age with NSTE-ACS
(defined as new-onset chest discomfort at rest or
with low levels of activity/or emotion within
the preceding 48 h) were eligible if they had an
elevated cardiac enzyme (troponin TC 0.03 ng/mL
or creatinine kinase-MB isoenzymeC 5.0 ng/mL).
Troponin T was measured by
electrochemiluminescence using the Roche
Elecsys analyzer, and creatinine kinase-MB was
measured by immunoassay using the Roche
Cobas analyzer (Roche, Basel, Switzerland).
Subjects without elevation in cardiac enzymes
were considered eligible if they had an elevated
NT-pro-brain natriuretic peptide (NT-proBNP;
C450 pg/mL), ST-segment depression
(C0.5 mm), or thrombolysis in myocardial
infarction (TIMI) risk score [2. Exclusion
criteria included ST-elevation myocardial
infarction, cardiogenic shock, congestive heart
failure, hemodynamic instability, use of
fibrinolytic therapy in the last 96 h, current
bleeding or bleeding disorder within the last
3 months that required transfusion, pregnancy,
contraindication to any study medication
(heparin, clopidogrel, or glycoprotein IIb/III
inhibitor), percutaneous coronary intervention
in the last 6 months, or inability to provide
written informed consent.
The study protocol was approved by the
University of Florida Institutional Review
Board. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
Women who provided written informed
consent were randomly assigned to a routine
invasive versus a selective invasive strategy.
Treatment assignment was performed by
opening a sealed opaque envelope. The
routine invasive group was recommended to
undergo coronary angiography within 48 h of
hospital admission. Cardiac catheterization
was recommended in the selective invasive
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group for refractory chest pain,
hemodynamic/electrical instability, left
ventricular systolic dysfunction, or an
abnormal myocardial perfusion stress test;
however, patient management decisions were
ultimately left to treating physician.
The primary outcome was the risk of major
bleeding. Major bleeding was defined as
significantly disabling intra-cranial or
intra-ocular bleeding, bleeding that required
intervention or transfusion, or at least 5 g/dL
drop in hemoglobin. The secondary outcome
was the first occurrence of all-cause death,
myocardial infarction, stroke,
re-hospitalization for ACS, or major bleeding
within 6 months. Myocardial infarction was
defined as an elevation in creatine kinase-MB
isoenzyme greater than the upper limit of
normal which occurred spontaneously or in
the setting of percutaneous coronary
intervention. Myocardial infarction in the
setting of coronary artery bypass grafting
required the presence of new Q-waves [9, 10].
Urgent hospitalization was defined as the need
for hospitalization due to an ACS (ST-elevation,
non-ST-elevation, or unstable angina) regardless
of the treatment delivered (e.g., urgent
revascularization versus conservative therapy).
Stroke was defined as an ischemic event that
caused disabling neurological symptoms that
are present for more than 24 h. Urgent target
vessel revascularization was defined as recurrent
ischemic symptoms that resulted in the need for
repeat percutaneous intervention or surgical
revascularization. Risk ratio (RR) with 95%
confidence interval (CI) for the outcomes was
reported. Survival analyses were performed
using the Kaplan–Meier method, and the
log-rank test was used to compare differences
of event-free survival between the two arms. All
analyses were performed using SAS 9.3 (SAS
Institute, Cary, NC, USA).
RESULTS
Twenty-three women were assigned to routine
invasive therapy and 17 to selective invasive
therapy. All women had 6-month follow-up
(24 women followed to 12 months and
13 women to 24 months). Figure 1 summarizes
the study flow diagram. Women were
60 ± 13 years of age, 25% had diabetes, 43%
were current smokers, and 68% had a history of
hypertension (Table 1). The majority of women
received aspirin (98%), beta blockers (88%), and
statins (80%). Twenty-seven women (68%) had
elevated troponin T (mean 0.33 ng/mL) and/or
creatinine kinase-MB (mean 23 ng/mL).
One woman randomized to routine invasive
therapy subsequently refused catheterization.
In this group, the mean time from
randomization to catheterization was
11.7 ± 23.2 h. In the routine invasive group,
three women underwent successful
percutaneous coronary intervention, while in
three women a chronic occlusion was unable to
be re-vascularized. In the selective invasive
strategy group, catheterization was performed
for electrical/hemodynamic instability (n = 4),
low ejection fraction (n = 3), abnormal stress
test (n = 2), and refractory chest pain (n = 1). In
the selective invasive group, two women
underwent successful percutaneous coronary
intervention. Except for one patient in the
routine invasive group, catheterization was
exclusively performed by femoral artery access.
Only one patient in the routine invasive
therapy encountered major bleeding. At
6 months, the composite outcome
(intention-to-treat) occurred in 9% of the
routine invasive group versus 18% of the
selective invasive group (RR = 0.49, 95% CI
0.09–2.63, P = 0.63). Additional outcomes are
provided in Table 2. At a mean follow-up of
12.5 months, there was a non-significant
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benefit favoring routine invasive therapy
(log-rank P = 0.11).
DISCUSSION
Among women with NSTE-ACS, a routine
invasive therapy appeared to be safe with no
signal for an increase in major bleeding.
Although not powered for clinical outcomes,
there were numerically fewer adverse
cardiovascular events among the routine
invasive therapy group. The control arm of
our study received selective invasive therapy,
which is distinct from conservative therapy.
Accordingly, patients underwent monitoring
and additional risk stratification during their
hospitalization. As a result, many patients
crossed over to invasive therapy. However, we
do not consider these crossovers to be a
limitation, but rather a reality of clinical care.
Although prior meta-analyses had
demonstrated the benefits of a routine
invasive approach [11, 12], it is important to
emphasis that NSTE-ACS clinical trials have
shown a remarkable degree of sex bias. In a
pooled analysis of ACS trials, women comprised
only 25% of the patient population [13].
Furthermore, evidence had shown that
Fig. 1 Study ﬂow diagram. NSTE-ACS non-ST-elevation acute coronary syndrome, TIMI thrombolysis in myocardial
infarction
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Table 1 Baseline characteristics of the study cohort





Age, years (mean ± SD) 60 ± 13 58 ± 15 62 ± 10 0.30
Body mass index, kg/m2
(mean ± SD)
28 ± 9 30 ± 9 26 ± 9 0.19
History of [n (%)]
Diabetes 10 (25) 5 (22) 5 (29) 0.72
Current smoking 17 (43) 10 (43) 7 (41) [0.99
Hypertension 27 (68) 14 (61) 13 (76) 0.33
Hypercholesterolemia 21 (53) 14 (61) 7 (41) 0.34
Myocardial infarction 7 (18) 6 (26) 1 (6) 0.21
Stroke/transient ischemic attack 6 (15) 5 (22) 1 (6) 0.20
Percutaneous coronary
intervention
8 (20) 7 (30) 1 (6)
Coronary artery bypass grafting 2 (5) 2 (9) 0 (0) 0.50
Medications at randomization [n (%)]
Aspirin 39 (98) 22 (96) 17 (100) [0.99
Clopidogrel 26 (65) 14 (61) 12 (71) 0.74
ACE inhibitor/ARB 33 (83) 18 (78) 15 (88) [0.99
Beta blocker 35 (88) 20 (87) 15 (88) [0.99
Statin 32 (80) 19 (83) 13 (76) 0.70
Insulin 7 (18) 3 (13) 4 (24) 0.43
Laboratory data (mean ± SD)
Total cholesterol, mg/dL 179 ± 46 (n = 30) 173 ± 39 (n = 18) 188 ± 55 (n = 12) 0.40
Triglycerides, mg/dL 164 ± 102 (n = 30) 170 ± 104 (n = 18) 154 ± 103 (n = 12) 0.66
HDL cholesterol, mg/dL 47 ± 16 (n = 30) 48 ± 16 (n = 18) 47 ± 16 (n = 13) 0.86
LDL cholesterol, mg/dL 113 ± 77 (n = 29) 115 ± 93 (n = 18) 110 ± 44 (n = 12) 0.87
CK-MB, ng/mLa 23 ± 19 (n = 19) 25 ± 20 (n = 9) 21 ± 18 (n = 10) 0.67
Troponin T, ng/mLa 0.33 ± 0.44
(n = 25)
0.38 ± 0.60 (n = 12) 0.29 ± 0.20 (n = 13) 0.62
NT-proBNP, pg/mLa 4636 ± 4775
(n = 8)
3913 ± 3716 (n = 5) 5841 ± 6980 (n = 3) 0.62
Risk scores
TIMIb 3 ± 1 3 ± 1.4 3 ± 1.6 0.45
GRACEb 103 ± 29 98 ± 31 110 ± 27 0.21
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bleeding events are higher in women
undergoing percutaneous coronary
interventions compared with men [14, 15].
Therefore, this pilot study aimed to address
the question whether a routine invasive
approach would be safe. Although the OASIS-5
sub-study had addressed this same question, the
bleeding events in that study were remarkably
high which could have been attributed to the
study design [6].
Although we attempted to enroll high-risk
women, the proportion of women who
underwent revascularization was low (i.e.,
\20%). Approximately one-fifth of women
had a chronic total occlusion, which is similar
to previous findings [16]. While 68% of our
study participants were eligible due to elevated
cardiac enzymes, the remainder met other
eligibility characteristics which might not
adequately risk-stratified patients. However,
Table 1 continued





HAS-BLEDb 1 ± 1 1 ± 0.99 1 ± 0.94 0.95
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CK-MB creatine kinase-myocardial band, HDL
high-density lipoprotein, LDL low-density lipoprotein, NT-proBNP N-terminal-pro brain natriuretic peptide, SD standard
deviation
a Means obtained among those with CK-MB C 5.0 ng/mL, troponin T C 0.03 ng/mL, and NT-proBNP C 450 pg/mL for
each category
b Median was reported
Table 2 Six-month outcomes
Routine invasive
(n5 23) n (%)
Selective invasive
(n5 17) n (%)
P value
Composite outcomea
Intention to treat 2 (9) 3 (18) 0.63
Actual treatment received 2 (9) 4 (24) 0.26
Other outcomes
Death 0 (0) 1 (6)b 0.43
MI 0 (0) 0 (0) –
Stroke 0 (0) 1 (6) 0.43
Urgent hospitalization for ACS 1 (4) 2 (12) 0.56
Major bleeding 1 (4) 0 (0) 0.99
Death, MI, stroke, re-hospitalization for ACS 1 (4) 3 (18) 0.29
ACS acute coronary syndrome, MI myocardial infarction
a Death, MI, re-hospitalization for ACS, stroke, or major bleeding
b Death occurred in a patient with acute lymphoblastic leukemia
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the median TIMI risk score was 3 and in the
TACTICS-TIMI 18 trial, intermediate- to
high-risk patients (score C 3) benefited from
invasive therapy [17]. Current guidelines
recommend routine invasive therapy for
high-risk women (i.e., elevated troponin);
however, routine invasive therapy is less
favorable in low-risk NSTE-ACS women [18].
Based on our observed 6-month event rate of
18% in the selective invasive arm, we estimate
that 3454 patients would be needed to detect a
20% relative difference between treatment arms
with 80% power.
CONCLUSION
This study demonstrates that a routine invasive
approach is safe in women. There was
suggestion of benefit from routine invasive
therapy compared with selective invasive
therapy. These data could be used to design an
appropriately powered trial to determine the
optimal management strategy among women
with NSTE-ACS.
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